Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CEMI's Cash to Debt is ranked higher than
96% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. CEMI: No Debt )
CEMI' s 10-Year Cash to Debt Range
Min: 0.21   Max: No Debt
Current: No Debt

Equity to Asset 0.79
CEMI's Equity to Asset is ranked higher than
87% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. CEMI: 0.79 )
CEMI' s 10-Year Equity to Asset Range
Min: -2.07   Max: 0.82
Current: 0.79

-2.07
0.82
Interest Coverage No Debt
CEMI's Interest Coverage is ranked higher than
78% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 178.70 vs. CEMI: No Debt )
CEMI' s 10-Year Interest Coverage Range
Min: 28.82   Max: 9999.99
Current: No Debt

28.82
9999.99
F-Score: 2
Z-Score: 4.96
M-Score: -1.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -5.61
CEMI's Operating margin (%) is ranked higher than
67% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.24 vs. CEMI: -5.61 )
CEMI' s 10-Year Operating margin (%) Range
Min: -93.86   Max: 15.41
Current: -5.61

-93.86
15.41
Net-margin (%) -4.12
CEMI's Net-margin (%) is ranked higher than
68% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. CEMI: -4.12 )
CEMI' s 10-Year Net-margin (%) Range
Min: -93.74   Max: 32.02
Current: -4.12

-93.74
32.02
ROE (%) -5.66
CEMI's ROE (%) is ranked higher than
68% of the 272 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. CEMI: -5.66 )
CEMI' s 10-Year ROE (%) Range
Min: -8840.71   Max: 67.84
Current: -5.66

-8840.71
67.84
ROA (%) -4.71
CEMI's ROA (%) is ranked higher than
68% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. CEMI: -4.71 )
CEMI' s 10-Year ROA (%) Range
Min: -1866.67   Max: 50.54
Current: -4.71

-1866.67
50.54
ROC (Joel Greenblatt) (%) -17.45
CEMI's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. CEMI: -17.45 )
CEMI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3301.06   Max: 98.41
Current: -17.45

-3301.06
98.41
Revenue Growth (3Y)(%) 8.50
CEMI's Revenue Growth (3Y)(%) is ranked higher than
81% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. CEMI: 8.50 )
CEMI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 26.4
Current: 8.5

0
26.4
» CEMI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CEMI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 232.56
CEMI's Forward P/E is ranked higher than
69% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CEMI: 232.56 )
N/A
P/B 2.30
CEMI's P/B is ranked higher than
82% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. CEMI: 2.30 )
CEMI' s 10-Year P/B Range
Min: 1.41   Max: 20.4
Current: 2.3

1.41
20.4
P/S 1.60
CEMI's P/S is ranked higher than
84% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.51 vs. CEMI: 1.60 )
CEMI' s 10-Year P/S Range
Min: 0.19   Max: 11.85
Current: 1.6

0.19
11.85
EV-to-EBIT -25.60
CEMI's EV-to-EBIT is ranked lower than
51% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CEMI: -25.60 )
CEMI' s 10-Year EV-to-EBIT Range
Min: -43.7   Max: 172
Current: -25.6

-43.7
172
Shiller P/E 20.90
CEMI's Shiller P/E is ranked higher than
96% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CEMI: 20.90 )
CEMI' s 10-Year Shiller P/E Range
Min: 13.17   Max: 21.36
Current: 20.9

13.17
21.36
Current Ratio 3.34
CEMI's Current Ratio is ranked higher than
76% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. CEMI: 3.34 )
CEMI' s 10-Year Current Ratio Range
Min: 0.03   Max: 5
Current: 3.34

0.03
5
Quick Ratio 2.65
CEMI's Quick Ratio is ranked higher than
75% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. CEMI: 2.65 )
CEMI' s 10-Year Quick Ratio Range
Min: 0.03   Max: 5
Current: 2.65

0.03
5
Days Inventory 80.18
CEMI's Days Inventory is ranked higher than
78% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 141.40 vs. CEMI: 80.18 )
CEMI' s 10-Year Days Inventory Range
Min: 37.8   Max: 87.12
Current: 80.18

37.8
87.12
Days Sales Outstanding 110.10
CEMI's Days Sales Outstanding is ranked higher than
64% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 84.80 vs. CEMI: 110.10 )
CEMI' s 10-Year Days Sales Outstanding Range
Min: 18.22   Max: 116.23
Current: 110.1

18.22
116.23

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 3.60
CEMI's Price/Net Current Asset Value is ranked higher than
90% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CEMI: 3.60 )
CEMI' s 10-Year Price/Net Current Asset Value Range
Min: 2.2   Max: 37.33
Current: 3.6

2.2
37.33
Price/Tangible Book 2.29
CEMI's Price/Tangible Book is ranked higher than
90% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.30 vs. CEMI: 2.29 )
CEMI' s 10-Year Price/Tangible Book Range
Min: 1.29   Max: 3425.19
Current: 2.29

1.29
3425.19
Price/DCF (Projected) 3.81
CEMI's Price/DCF (Projected) is ranked higher than
78% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CEMI: 3.81 )
CEMI' s 10-Year Price/DCF (Projected) Range
Min: 1.57   Max: 14
Current: 3.81

1.57
14
Price/Median PS Value 1.27
CEMI's Price/Median PS Value is ranked higher than
64% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. CEMI: 1.27 )
CEMI' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 1.43
Current: 1.27

0.32
1.43
Earnings Yield (Greenblatt) -3.90
CEMI's Earnings Yield (Greenblatt) is ranked higher than
57% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. CEMI: -3.90 )
CEMI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 11.2
Current: -3.9

0.6
11.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Chembio Diagnostics Inc was formed in 1985. The Company with its subsidiaries develops, manufacture and market diagnostic tests that detect infectious diseases. The Company's main products presently commercially available are four rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, all of which Employ lateral flow technology, and two of which were approved by the FDA in 2006. The Company's products are sold to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals and retail establishments both domestically and internationally. The Company's products are sold under its STAT PAK, SURE CHECK or DPP registered trademarks. The Company's HIV tests are qualitative (reactive/non-reactive) tests. Many of its competitors are substantially larger and have greater financial, research, manufacturing and marketing resources. The manufacturing and marketing of the Company's existing and proposed diagnostic products are regulated by the United States Food and Drug Administration ('FDA'), United States Department of Agriculture ('USDA'), certain state and local agencies, and/or comparable regulatory bodies in other countries.
» More Articles for CEMI

Headlines

Articles On GuruFocus.com
comment on CEMI Mar 06 2013 
comment on CEMI Mar 06 2013 

More From Other Websites
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 01 2015
Chembio Launches HIV Self-Testing Initiative in Europe Apr 29 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Apr 28 2015
Chembio to Host Conference Call to Discuss First Quarter 2015 Financial Results Apr 27 2015
Chembio to Host Conference Call to Discuss First Quarter 2015 Financial Results Apr 27 2015
Chembio to Host Conference Call to Discuss First Quarter 2015 Financial Results Apr 27 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure Apr 24 2015
Document for Chembio Diagnostics, Inc. Apr 15 2015
Concussion talk no longer taboo: Ex-NFL star Mar 18 2015
CHEMBIO DIAGNOSTICS, INC. Financials Mar 12 2015
Chembio Diagnostics Reports 2014 Financial Results Mar 05 2015
Chembio Diagnostics Reports 2014 Financial Results Mar 05 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 05 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 10-K, Annual Report Mar 05 2015
Q4 2014 Chembio Diagnostics Inc Earnings Release - Before Market Open Mar 05 2015
Chembio to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and Webcast Live on... Mar 04 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 23 2015
Chembio to Host Conference Call to Discuss 2014 Financial Results Feb 23 2015
Chembio to Host Conference Call to Discuss 2014 Financial Results Feb 23 2015
Chembio's DPP(R) HIV-Syphilis Assay Cleared for Launch in Brazil Feb 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK